Pharmesis International Ltd.
Climate Impact & Sustainability Data (2020, 2022)
Reporting Period: 2020
Environmental Metrics
ESG Focus Areas
- Economic Performance
- Product Quality and Safety
- Occupational Health and Safety
Social Achievements
- Achieved zero drug safety incident in FY2020.
- Achieved zero workplace injuries in FY2020.
Climate Goals & Targets
Environmental Challenges
- COVID-19 pandemic causing suspension of operations in Q1 2020.
- Intense competition and pricing pressure in the PRC pharmaceutical industry.
- Withdrawal of Anethole Trithione (ATT) from government-backed insurance plans.
- Expansion of National Drug Centralized Procurement Pilot Scheme (4+7 Scheme) impacting drug pricing.
Supply Chain Management
Responsible Procurement
- Commitment to responsible sourcing to assure safety and quality of end products.
Climate-Related Risks & Opportunities
Reporting Standards
Frameworks Used: GRI Standards, SGX-ST Practice Note 7.6 Sustainability Reporting Guide
Reporting Period: 2022
Environmental Metrics
ESG Focus Areas
- Economic Performance
- Product Quality and Safety
- Occupational Health and Safety
Social Achievements
- Achieved zero drug safety incident in FY2022.
- Achieved zero workplace injuries in FY2022.
Governance Achievements
- Directors and management attended updated sustainability training in-line with the SGX enhanced requirements on sustainability reporting (Practice Note 7F) and TCFD.
Climate Goals & Targets
Environmental Challenges
- COVID-19 pandemic and related lockdowns in China affecting consumer spending and production.
- Record heat wave and drought impacting production.
Mitigation Strategies
- Group managed to minimise the decrease in revenue to 4.6% in FY2022 as compared to FY2021.
Supply Chain Management
Responsible Procurement
- Commitment to responsible sourcing to assure safety and quality of end products.
Climate-Related Risks & Opportunities
Reporting Standards
Frameworks Used: GRI Standards, SGX-ST Practice Note 7.6